What Is Kyntra Bio, Inc. (KYNB) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Kyntra Bio, Inc. presents a highly debated valuation profile at its current price of $7.21. The composite intrinsic value is estimated at $11.52 (+59.8% average upside), masking a wide model spread between the 4 bullish models and 4 bearish models. Model dispersion is worth noting: CUCE targets $30.55 (+323.7%), versus Regime Cross at $1.70 (-76.5%). This +400.2% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About KYNB?
8 of 13 models are currently active for KYNB. Of these, 4 models suggest upside while 4 models suggest overvaluation. The Bayesian DCF estimates KYNB's intrinsic value at $16.17, implying +124.3% upside from the current price. See which stocks rank higher →
How Does KYNB Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, KYNB ranks #240 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to biopharma enterprise businesses. For Kyntra Bio, Inc., metrics like patent cliff exposure provide important context that general-purpose valuation models may underweight.
Is KYNB a Value Trap?
CirclFi's Value Trap algorithm assigns KYNB a score of 32/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
8 of 13 models are active for Kyntra Bio, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Kyntra Bio, Inc. scores 4.8 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +400.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every KYNB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across KYNB's 8 active models, average confidence is 28%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad